Influenza A and B

Active Ingredient: Zanamivir

Indication for Zanamivir

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Preventive action

Zanamivir is indicated for post-exposure prophylaxis of influenza A and B in adults and children (≥5 years) following contact with a clinically diagnosed case in a household. In exceptional circumstances, zanamivir may be considered for seasonal prophylaxis of influenza A and B during a community outbreak (e.g. in case of a mismatch between circulating and vaccine strains and a pandemic situation).

Zanamivir is not a substitute for influenza vaccination. The appropriate use of zanamivir for prevention of influenza should be determined on a case-by-case basis depending on the circumstances and the population requiring protection.

The use of antivirals for the treatment and prevention of influenza should take into consideration official recommendations, the variability of epidemiology, and the impact of the disease in different geographical areas and patient populations.

For this indication, competent medicine agencies globally authorize below treatments:

10 mg once daily for 10 days for post-exposure prophylaxis, and for 28 days for seasonal prophylaxis

For:

Dosage regimens

Regimen A: In case that patient age in years is ≥ 5 and there is exposure to Influenzavirus, respiratory (Inhalation), 10 milligrams zanamivir, once daily, over the duration of 10 days.

Regimen B: In case that patient age in years is ≥ 5, respiratory (Inhalation), 10 milligrams zanamivir, once daily, over the duration of 28 days.

Detailed description

Post-exposure prophylaxis

The recommended dose of zanamivir for prevention of influenza, following close contact with an individual, is 10 mg once daily for 10 days. Therapy should begin as soon as possible and within 36 hours of exposure to an infected person.

Seasonal prophylaxis

The recommended dose of zanamivir for prevention of influenza during a community outbreak is 10 mg once daily for up to 28 days.

Active ingredient

Zanamivir

Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract. The activity of zanamivir is extracellular. It reduces the propagation of both influenza A and B viruses by inhibiting the release of infectious influenza virions from the epithelial cells of the respiratory tract.

Read more about Zanamivir

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.